<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59008">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337816</url>
  </required_header>
  <id_info>
    <org_study_id>ENDOMETAB01</org_study_id>
    <nct_id>NCT02337816</nct_id>
  </id_info>
  <brief_title>Role of Metabolomics in the Diagnosis of Endometriosis</brief_title>
  <official_title>Role of Metabolomics in the Diagnosis of Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cagliari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cagliari</source>
  <brief_summary>
    <textblock>
      Endometriosis is one of the most common benign gynecological, affecting about 10% of
      premenopausal women. The pathophysiology of this disease is still not completely clear.
      Despite its prevalence, there is no blood test available for the diagnosis of endometriosis
      and the average delay time to diagnosis is 9.4 years.

      Metabolomics is a scientific discipline that studies changes in metabolites related to the
      pathophysiology of the disease.

      Aim of the study is to identify an alteration in the expression of the metabolites in women
      with endometriosis
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and urine concentration of metabolites</measure>
    <time_frame>At least one month after discontinuation of hormonal therapies , before laparoscopic surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Endometriosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo laparoscopic surgery in order to treat endometriosis. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood, with the purpose to study metabolitis, will be collected before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo laparoscopic surgery in order to treat benign gynecological diseases. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood,with the purpose to study metabolitis, will be collected before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic surgery, obtainment of biological samples</intervention_name>
    <arm_group_label>Endometriosis</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women of childbearing age ;

          -  written consent to laparoscopic surgery;

          -  written consent to the study .

        Exclusion Criteria:

          -  Suspicion or diagnosis of malignant disease

          -  Inability or unwillingness to provide written consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 9, 2016</lastchanged_date>
  <firstreceived_date>January 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cagliari</investigator_affiliation>
    <investigator_full_name>Stefano Angioni</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>Metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
